Latest news with #Candid
Straits Times
a day ago
- Business
- Straits Times
Candid Mixers and PT Sukanda Djaya Announce Strategic Distribution Partnership
JAKARTA, Indonesia, Aug. 19, 2025 /PRNewswire/ -- Scaling Indonesia's First Premium Mixer Brand Nationwide Just two days after Indonesia commemorates 80 years of independence, a bold wave of local innovation takes center stage in the beverage industry. Candid Mixers - the country's first homegrown premium mixer brand - is proud to announce a nationwide distribution agreement with PT Sukanda Djaya (SKD), one of Indonesia's most trusted food and beverage distributors. Now pouring at Indonesia's top bars - Candid Mixers, proudly made and delivered across the archipelago by SKD This partnership marks a milestone moment: an Indonesian-made, bartender-led mixer brand going national with the full force of SKD's logistics and retail expertise behind it. "Candid Mixers brings an exciting new dimension to the beverage landscape in Indonesia. As the country's first locally produced premium mixer brand, it reflects both innovation and quality - values we're proud to support as we scale their reach nationwide." - PT Sukanda Djaya Under the agreement, SKD will distribute Candid's signature 250 ml SKUs including Imperial Tonic, Club Soda, and Ginger Ale across hotels, bars, clubs, and premium retail channels. New flavours are also on the horizon. Crafted in Indonesia. Designed for the World. Created by local bartenders and proudly manufactured in Indonesia, Candid Mixers reflects a modern Indonesian spirit - ambitious, elevated, and ready to lead. Following a strong first half of 2025, the partnership arrives at a pivotal moment for the brand, fueled by increasing demand from hospitality venues seeking high-quality, wellness-aligned beverage options. Candid has already earned attention nationwide for its bold flavour profiles , design-forward identity, and versatile, alcohol-free appeal - whether poured into a cocktail or sipped straight from the can. And now, with the launch of Emma, Candid's AI Bartender, venues and consumers alike can unlock even more creativity. Emma can instantly suggest recipes for signature cocktails, craft alcohol-free pairings, or generate batch-ready serves for events - bringing Candid's premium mixers to life in new and innovative ways. Key Distribution Highlights: Direct fulfillment through SKD's trusted nationwide network Immediate availability expansion across hotels, bars, clubs, and modern grocers Launch of trial packs, retail-ready displays, and co-branded marketing in Q3 This partnership is more than logistics - it is a signal of Indonesia's growing place on the global beverage map, with Candid leading the way. Website: Images & Video: Google Drive Folder Meet Emma: Your AI Bartender Candid's new AI Bartender, Emma, can create drink ideas for any occasion - whether you need a refreshing mocktail for a spa day, a signature cocktail for your bar menu, or a batch serve for an event. Try Emma now - see 3 mocktail and 2 cocktail recipes using Candid Imperial Tonic, one for poolside and one for a night out .
Korea Herald
a day ago
- Business
- Korea Herald
Candid Mixers and PT Sukanda Djaya Announce Strategic Distribution Partnership
JAKARTA, Indonesia, Aug. 19, 2025 /PRNewswire/ -- Scaling Indonesia's First Premium Mixer Brand Nationwide Just two days after Indonesia commemorates 80 years of independence, a bold wave of local innovation takes center stage in the beverage industry. Candid Mixers - the country's first homegrown premium mixer brand - is proud to announce a nationwide distribution agreement with PT Sukanda Djaya (SKD), one of Indonesia's most trusted food and beverage distributors. This partnership marks a milestone moment: an Indonesian-made, bartender-led mixer brand going national with the full force of SKD's logistics and retail expertise behind it. "Candid Mixers brings an exciting new dimension to the beverage landscape in Indonesia. As the country's first locally produced premium mixer brand, it reflects both innovation and quality - values we're proud to support as we scale their reach nationwide." - PT Sukanda Djaya Under the agreement, SKD will distribute Candid's signature 250 ml SKUs including Imperial Tonic, Club Soda, and Ginger Ale across hotels, bars, clubs, and premium retail channels. New flavours are also on the horizon. Crafted in Indonesia. Designed for the World. Created by local bartenders and proudly manufactured in Indonesia, Candid Mixers reflects a modern Indonesian spirit - ambitious, elevated, and ready to lead. Following a strong first half of 2025, the partnership arrives at a pivotal moment for the brand, fueled by increasing demand from hospitality venues seeking high-quality, wellness-aligned beverage options. Candid has already earned attention nationwide for its bold flavour profiles, design-forward identity, and versatile, alcohol-free appeal - whether poured into a cocktail or sipped straight from the can. And now, with the launch of Emma, Candid's AI Bartender, venues and consumers alike can unlock even more creativity. Emma can instantly suggest recipes for signature cocktails, craft alcohol-free pairings, or generate batch-ready serves for events - bringing Candid's premium mixers to life in new and innovative ways. Key Distribution Highlights: This partnership is more than logistics - it is a signal of Indonesia's growing place on the global beverage map, with Candid leading the way. Candid's new AI Bartender, Emma, can create drink ideas for any occasion - whether you need a refreshing mocktail for a spa day, a signature cocktail for your bar menu, or a batch serve for an event.
Malaysian Reserve
17-07-2025
- Business
- Malaysian Reserve
Liberty HealthShare Gets Another GuideStar Gold Seal
Earned GuideStar Gold Seal Four Straight Years Received Charity Navigator 4-Star Rating for 2025 Only Healthshare Ministry with Both Gold Seal and 4-Star Rating CANTON, Ohio, July 17, 2025 /PRNewswire/ — For the fourth straight year, Liberty HealthShare® has been awarded the GuideStar Gold Seal by Candid, ranking it among the country's best non-profit organizations for transparency and accountability. The Gold Seal recognizes non-profits for sharing information about their finances, leadership, demographics, programs, organization, and mission. Less than two percent of the 1.8 million organizations included on Candid have earned a Gold Seal. 'We are pleased to have been recognized with the 2025 Gold Seal from Candid,' said Dorsey Morrow, Liberty HealthShare chief executive officer. 'Combined with our 4-star rating from Charity Navigator, it demonstrates our commitment to accountability and operational excellence. We strive to be a good steward of our members' contributions.' Liberty HealthShare is the only healthshare ministry in the United States to hold both the GuideStar Gold Seal and Charity Navigator's 4-Star rating. Candid's GuideStar rankings are the world's largest source of information on non-profit organizations. Its mission is to revolutionize philanthropy by providing information that advances transparency, enables users to make better decisions, and encourages charitable giving. Candid was formed in 2019 when GuideStar and Foundation Center merged. Charity Navigator reviews more than 200,000 non-profit organizations on their accountability and finance, impact and results, culture and community, and leadership and adaptability. Liberty HealthShare's 90% score for 2025 is its highest rating ever. Established in 1995, Liberty HealthShare provides a cost-effective, faith-based alternative to health insurance. Members enjoy the freedom to choose their own providers while participating in a compassionate, Christian community. Transparency and stewardship are central, with programs tailored for families, seniors, and individuals. 'While healthcare costs rise across the country, Liberty HealthShare is able to offer our members an alternative to insurance that provides greater value at lower costs,' said Morrow. Liberty HealthShare offers six affordable medical cost sharing programs that are designed to fit the needs and budgets of individuals as well as different types and sizes of families. Suggested monthly share amounts for individuals range from $87–$369. Share amounts for families of four start at $319 per month. Most programs include access to both urgent care and mental wellness telehealth visits along with access to discounts for prescription drugs, dental care, vision care, and even LASIK surgery. Liberty Dental, the ministry's dental sharing program, features suggested monthly share amounts as low as $35 and allows members to see the dentist of their choice without any network restrictions. As Liberty HealthShare is not insurance, enrollment is available year-round with no requirement for special life events to qualify. For more information about its sharing programs visit or call (855) 585-4237. Earlier this year, Liberty HealthShare established the Sharing Hearts Fund for Pediatric Wellness, a charitable arm of the ministry that seeks to provide support to Stark County, Ohio families with medical needs related to pediatric wellness. Liberty HealthShare is a non-profit 501(c) (3) charitable Christian medical cost-sharing ministry focused on members helping each other in times of need. The faith-based program, which facilitates healthsharing for its members, is a caring community of health-conscious individuals and families who choose to support one another and agree to the Christian values of stewardship to make healthcare affordable for all. Liberty HealthShare is not an insurance company nor is it offered through an insurance company. Liberty HealthShare's Sharing Programs do not guarantee or promise that a member's medical bills will be paid or assigned to others for payment. Whether anyone chooses to pay a member's medical bills will be totally voluntary. As such, Liberty HealthShare's Sharing Programs should never be considered as a substitute for an insurance policy. Whether a member receives any payments for medical expenses and whether or not Liberty HealthShare continues to operate, the member is always liable for any unpaid bills.
Business Wire
20-06-2025
- Business
- Business Wire
Candid Therapeutics Advances Portfolio of Novel T-Cell Engagers into Five Autoimmune Diseases for Clinical Evaluation
SAN DIEGO--(BUSINESS WIRE)--Candid Therapeutics, Inc. ('Candid'), a clinical-stage biotechnology company redefining the treatment of autoimmune and inflammatory diseases through novel T-cell engagers (TCEs), today announced key operational and clinical milestones for its two lead clinical stage programs, cizutamig (BCMA TCE) and CND261 (CD20 TCE). Candid launched in the second half of 2024 with $370 million in financing and two in-licensed TCEs that had completed full Phase 1 dose escalation studies in oncology patients. Emerging clinical data with TCEs have solidified our confidence that TCEs can become the most compelling modality across a range of diseases. Share 'We founded Candid on the conviction that T-cell engagers would become the largest therapeutic class in autoimmune diseases, surpassing the commercial success of TNF inhibitors such as Humira,' said Dr. Ken Song, Chairman, President, and Chief Executive Officer of Candid. 'We are hyperfocused on execution to generate clinical data. Over the past few quarters, we have prioritized disease indications and built a foundation of key CMC and clinical operational activities to set a new benchmark for innovation, scale, and speed. Emerging clinical data with TCEs have solidified our confidence that TCEs can become the most compelling modality across a range of diseases.' Key Highlights Reinforcing Candid's Leadership Position: First patients dosed with cizutamig and CND261: Patients with refractory rheumatoid arthritis and systemic sclerosis have been dosed at therapeutically active doses. Both TCEs have been well tolerated and patients have shown early signs of promising clinical response and disease improvement. Industry-leading clinical study pipeline in motion: Clinical studies are now in progress for IgA Nephropathy, Myasthenia Gravis, Rheumatoid Arthritis, Systemic Lupus Erythematosus and Systemic Sclerosis. Additional clinical studies in high-value disease indications slated to launch in the 2H 2025. Studies are designed to evaluate safety, pharmacokinetics, pharmacodynamic effects, and early signs of efficacy in patients with immunology and inflammatory diseases. CMC activities completed to enable global clinical trials: Candid has invested significant resources to build an integrated Chemistry, Manufacturing, and Controls (CMC) infrastructure to support global development with the completion of several new drug product manufacturing runs. Subcutaneous dosing formulations for both cizutamig and CND261 have been established. Strategic establishment of China operations: To support clinical execution across multiple geographies, Candid has established a fully staffed legal entity in China. The China based team includes professionals with deep expertise in regulatory, clinical development, and clinical operations. With unmatched executional momentum and differentiated programs, Candid Therapeutics is defining a new future in immunology through its commitment to TCEs in autoimmune diseases. Additional trial initiations and clinical data disclosures are anticipated in the coming quarters. About Candid Therapeutics Candid Therapeutics is a clinical-stage biotechnology company focused on transforming the treatment of autoimmune and inflammatory diseases through novel T-cell engager (TCE) platforms. Candid is advancing two lead B-cell depleting TCE antibody drug candidates, with a goal to broadly explore the potential of TCEs across multiple autoimmune diseases by targeting different B-cell protein targets, as well as evaluating different depths of B-cell depletion. Established in 2024 and headquartered in San Diego, CA, Candid is led by a team of entrepreneurial executives who have a track record of advancing programs into and through development and is supported by a distinguished syndicate of premier life science investors. About Cizutamig Cizutamig is a bispecific antibody designed to simultaneously bind B-cell maturation antigen (BCMA) on B-cells and CD3 on T-cells, enabling T-cell–mediated cytotoxicity against BCMA-expressing B-cells. Originally developed and clinically evaluated in multiple myeloma, cizutamig has demonstrated patient experience in oncology settings and is now being investigated in autoimmune diseases where pathogenic B-cells play a critical role in disease progression. Cizutamig has the potential to deliver deep and selective B-cell depletion through its dual-targeting mechanism, offering a novel approach for treating a broad spectrum of immune-mediated disorders. About CND261 CND261 is a bispecific antibody designed to target CD20 on B-cells and CD3 on T-cells, enabling T-cell mediated cytotoxicity against CD20-expressing B-cells. Engineered with low CD3 affinity, CND261 is optimized to reduce the risk of excessive T-cell activation while maintaining potent and selective B-cell depletion. The molecule has demonstrated patient experience in B-cell malignancies and is now being investigated in autoimmune diseases where pathogenic B-cells contribute to disease progression. CND261 represents a promising therapeutic candidate for immune-mediated disorders with the potential for improved safety and efficacy through its targeted mechanism of action.
Los Angeles Times
12-06-2025
- Entertainment
- Los Angeles Times
A tale of two eras: Terri Lyne Carrington pays tribute to the revolutionary spirit of Max Roach on ‘We Insist 2025!'
'The more things change, the more they stay the same,' French writer Jean-Baptiste Alphonse Kerr said in 1849. Nearly 200 years later, that is sadly true of the greatest protest songs. In 2025, songs like Bob Dylan's 'Masters of War' and Sam Cooke's 'A Change Is Gonna Come' are as needed for their messages as they were when they were written more than 60 years ago. So when Grammy-winning jazz drummer Terri Lyne Carrington set out this year to pay homage to one of her stick-wielding idols, the legendary Max Roach, by revisiting his seminal 1961 album, 'We Insist!,' it turned out to be more than a musical tribute. In the process of recording the album 'We Insist 2025!,' Carrington took time to reflect on how issues of inequality, racism and more that Roach fought against in 1961 are unfortunately just as prevalent today. 'Wow, I can't believe that this stuff is still relevant,' Carrington says. 'When we look at these examples of how things have shifted in some ways, but not in other ways, it can be very depressing, especially right now. When we started this record, the election hadn't happened yet. I thought I knew what was going to happen during this election, and it was still relevant. But now it's even more relevant.' Now 59, Carrington, who also serves as Zildjian Chair in Performance at Berklee College of Music in Boston, is ready to pass along some of the fight for social justice to the younger generation. 'I do feel like it's a youthful game. I had an uncle that I would talk to when I was in my 20s, who has since passed. He would say that this is your fight now, and I would be mad at him, feeling like he wasn't doing more,' she recalls. 'And he would say, 'No, this is your fight now. I've done it, I've been there, I'm tired.' I get that sentiment too. I'm going to do whatever I do, but I'm relying on the younger generation and how pissed off I feel like they are and what that will do.' Among her many ventures to champion the jazz music she loves so much is A&R for iconic jazz label Candid Records, founded by the great jazz writer Nat Hentoff in 1960. So, she called on the younger generation to help share her vision of 'We Insist 2025!' 'I thought of calling the people that had been signed or were being signed to Candid Records because I do A&R for Candid. So I thought this would be a great opportunity to also shine a light on a lot of these artists, young people and progressive artists that are being signed right now to Candid. It's kind of like a family gathering; we all came together to pay tribute to this great artist and this great project,' she says. At the center of the next generation of jazz artists on the album is vocalist Christie Dashiell, with whom Carrington collaborates on the album. 'Somebody like Christie Dashiell was really important to the project, because I felt like the voice is so out front. It's what people relate to; the average ear relates to the voice the most,' Carrington says. 'I just feel like she perfectly embodies all these different areas of Black music traditions. That was really important, so I started there. What is the voice that's going to work with this idea?' Having toured with Herbie Hancock and played with giants as Dizzy Gillespie and Stan Getz, Carrington has a strong sense of jazz history and rightly sees herself as a bridge between the history and future of jazz. She made sure that bridge was strong on 'We Insist 2025!' by including trombonist Julian Priester on the record, who, at 89, is the last living musician who appeared on Roach's 1961 work. 'Jazz has always been about these kinds of bridges between generations. It's been such an important part of jazz. Mentorship, apprenticeships — it's an apprenticeship art form,' she says. 'So we did contemporary things with this music, but it wasn't so contemporary that there was no place for a Julian Priester. I think that the ability to be a bridge is important — pointing to past legacies, to the foundation of what we stand on, while trying to also point to the future or reflect the present is important.' As much as the album's original political message weighs in this turbulent current climate, and as much as Carrington wanted to make the record a vehicle for younger artists, the impetus for 'We Insist 2025!' was to pay tribute to Roach for the centennial anniversary of his birth. For Carrington, the heart of her interpretation was to honor the music and spirit Roach created on 'We Insist!' 'I had a history with reimagining projects in other people's work, and helping that legacy continue, but doing it in a way that also has my own identity involved in a way that really feels new, in a sense,' she says. 'The music is not new, but so many elements around those things are new. So I feel like it's reshaping these things a little, even though we didn't change the lyric content. By changing the music around the lyrics, it gives the lyric a different slant.' As one of the country's primary ambassadors of jazz music today, Carrington hopes the record will introduce new fans to Roach's considerable legacy while helping to revive the soul of protest music. To that end, she has discussed bigger plans with his family. 'I've talked to Max's son, Raul Roach, quite a bit about trying to collaborate by doing shows that would be expansive. Doing some of this music, maybe doing some other Max music, like some of the double quartet music,' she says. 'So we've talked about finding ways to continue this celebration of Max Roach and his artistry. There's a lot there as a foundation that can be expanded upon.'
